Search

Your search keyword '"Pavel, Petra"' showing total 6 results
Start Over Author "Pavel, Petra" Publisher american society of hematology
6 results on '"Pavel, Petra"'

1. Third-Generation Chimeric Antigen Receptor (CAR) T Cells in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) and Non-Hodgkin Lymphoma (NHL) - Results from the Heidelberg Trial 1 (HD-CAR-1 trial)

Author

Schubert, Maria-Luisa, primary, Schmitt, Anita, additional, Neuber, Brigitte, additional, Hückelhoven-Krauss, Angela, additional, Kunz, Alexander, additional, Wang, Lei, additional, Michels, Birgit, additional, Waldhoff, Philip, additional, Sellner, Leopold, additional, Korell, Felix, additional, Hofmann, Susanne, additional, Pavel, Petra, additional, Ho, Anthony D, additional, Müller-Tidow, Carsten, additional, Dreger, Peter, additional, and Schmitt, Michael, additional

Published
2021
Full Text
View/download PDF

3. CAR T cells or allogeneic transplantation as standard of care for advanced large B-cell lymphoma: an intent-to-treat comparison

Author

Dreger, Peter, primary, Dietrich, Sascha, additional, Schubert, Maria-Luisa, additional, Selberg, Lorenz, additional, Bondong, Andrea, additional, Wegner, Mandy, additional, Stadtherr, Peter, additional, Kimmich, Christoph, additional, Kosely, Florentina, additional, Schmitt, Anita, additional, Pavel, Petra, additional, Liebers, Nora, additional, Luft, Thomas, additional, Hegenbart, Ute, additional, Radujkovic, Aleksandar, additional, Ho, Anthony Dick, additional, Müller-Tidow, Carsten, additional, and Schmitt, Michael, additional

Published
2020
Full Text
View/download PDF

4. A Single Center Comparison Between Two Different Apheresis Systems for Peripheral Blood Stem Cell Collections

Author

Lisenko, Katharina, primary, Bruckner, Thomas, additional, Hundemer, Michael, additional, Schmitt, Anita, additional, Puthenparambil, Joe, additional, Pavel, Petra, additional, Hillengass, Jens, additional, Witzens-Harig, Mathias, additional, Goldschmidt, Hartmut, additional, Ho, Anthony D, additional, and Wuchter, Patrick, additional

Published
2015
Full Text
View/download PDF

6. Gene Therapy in Transfusion-Dependent Non-β0/β0 Genotype β-Thalassemia: First Real-World Experience of Beti-cel.

Author

Mirza A, Ritsert ML, Tao G, Thakar H, Lobitz S, Heine S, Koscher L, Dürken M, Schmitt A, Schmitt M, Pavel P, Laier S, Jakoby D, Greil J, Kunz JB, and Kulozik A

Abstract

Gene addition and editing strategies for transfusion-dependent β-thalassemia have gained momentum as potentially curative treatment options, with studies showcasing their efficacy and safety. We report the first real-world application of betibeglogene autotemcel (beti-cel; ZYNTEGLO™) during its period of active license in Europe from January 2020 to March 2022 for patients aged ≥ 12 years without a β0/β0 genotype and without a human leukocyte antigen (HLA)-matched sibling donor, before beti-cel marketing authorization was withdrawn by its holder due to non-safety reasons. Among 15 screened patients, 4 opted out for fertility and safety concerns, 2 were excluded because of marked hepatic siderosis, and 1 had apheresis collection failure. Eight patients received beti-cel post busulfan myeloablative conditioning, all achieving transfusion independence within 8 to 59 days with posttreatment hemoglobin levels ranging from 11.3 to 19.3 g/dL. No deaths occurred, but acute toxicity mirrored busulfan's known effects. Posttreatment platelet management faced challenges due to HLA-antibodies in 3 patients. Monitoring up to Month 24 revealed pituitary-gonadal endocrine dysfunction in all 3 female and in 2 of 5 male patients. Additionally, we observed unexpected posttreatment sequelae: 1 patient developed polycythemia that could not be explained by known genetic or acquired mechanisms, 1 patient developed posttreatment depression and anxiety prohibiting her from returning to work, and 1 patient developed fatigue severely compromising both quality of life and work capacity. This real-world experience corroborates beti-cel's efficacy and safety and provides information on adverse events observed during real-world use of the therapy., (Copyright © 2024 American Society of Hematology.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results